Thank you for submitting your manuscript to the EMBO Journal. I am sorry for the slight delay in getting back to you with a decision, but I have now heard back from the two referees who have reviewed your paper.
As you can see below, both referees appreciate the analysis and find it suitable for publication here. However, they also raise a number of issues that have to be resolved. In particular they find that further data would be needed to support the conclusion that IKKalpha regulates IRF3 mediated transcription via direct phosphorylation of IRF3. They offer a number of ways to address this issue. Given the referees' positive recommendations, I would like to invite you to submit a revised version of the manuscript, addressing the comments raised. I should add that it is EMBO Journal policy to allow only a single round of revision and that it is therefore important to resolve the raised issues at this stage.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html Thank you for the opportunity to consider your work for publication. I look forward to your revision.
REFEREE REPORTS Referee #1
In the submitted paper, the authors identified IKKalpha as an essential DC mediator required for T cell priming and acquired immunity. At the molecular level, they suggest the requirement for a TAK1-IKKalpha signaling cascade in IRF3-dependent regulation of IFNbeta expression in DC. The identification of IKKalpha and its role in DC maturation and IRF3 activation are important observations that will significantly contribute to our understanding of signaling cascades involved in bridging innate to acquired immunity.
General comments: Using knock-in mice that express a mutant form of IKKalpha that cannot be phosphorylated and activated (IKKalphaAA), they demonstrate the requirement of IKKalpha activation in the hematopoietic compartment for T cell priming and acquired immunity. The experiments are generally thorough and very well thought-out for this part of the study. With regard to the proposed role of the TAK1-IKKalpha module in the regulation of IRF3 transcription factor, there are additional points that deserve attention:
1) The authors need to show that TAK1 and IKKalpha are indeed activated using their conditions. In Fig. 5A , the authors proposed that polyI:C stimulation of BMDC resulted in an induced IKKalpha/beta phospho-signal in WB analysis. This panel actually shows IKKbeta phosphorylation (possibly at 87 kDa); the signal below this band (85 kDa) possibly corresponds to phosphoIKKalpha, which seemed constitutively phosphorylated in cultured BMDC. The use of a specific IKKalpha phosphospecific antibody is therefore required. In addition, polyI:C-induced TAK1 phosphorylation should be determined (a signal that should occur before IKKalpha/beta and IRF3 phosphorylation).
2) In the context of the IFNbeta enhanceosome, ATF-2/cJun heterodimers (AP1 transcription factors) are also involved in IFNbeta gene transcription. Does the use of the TAK1 inhibitor also affect the activation of p38/JNK protein kinases?
3) Figure 5 relies on the use of drug inhibitors. Other molecular means such as RNA interference should also be employed to take into consideration the possible "off-target" effects of the pharmacological approach. In addition, the proteasome inhibitor MG132 is not an NF-kappaB inhibitor; it inhibits the degradation of all proteins targeted to the proteasome. Other inhibitors, such as MLN4924, prevent the NEDDylation and hence the activation of SCFβTRCP (and other Cullinbased RING E3 ligases) and block the polyubiquitylation of phosphorylated IkappaBalpha and therefore its degradation.
4) The proposed TAK1-IKKalpha axis (pages 16 and 17) is rather weak and should be carefully discussed. In the present version of the manuscript, I am not convinced that the use of the TAK1 inhibitor prevented IKKalpha phosphorylation (see comment #1). In addition, a TAK1-JNK cascade (independent of IKKalpha) was previously proposed to be involved in IRF3 function (Zhang et al., Cell Research 2009). 5) The authors conclude that IKKalpha regulates IRF3-mediated transcription downstream of IKKe/TBK1, possibly through direct phosphorylation of IRF3 (Figure 7 ). At this stage, the presented data do not support such a conclusion:
A constitutively active form of IRF3 (called IRF3/5D) is used to by-pass TBK1 in MEFs. The use of this construct alone led to a strong transactivation of the IFNbeta promoter in an IKKalphadependent manner (Fig. 7C) . The authors suggest that this might occur through direct phosphorylation of the C-terminal regulatory domain (aa 396-405) of IRF3 by recombinant IKKalpha (Fig. 7D ). This conclusion is mechanistically is not supported by the presented data as the IRF3/5D mutant, in which all the available S/T residues were replaced by aspartic acid (thus can-not be phosphorylated), was functional in the IKKalpha-dependent reporter gene assay. Fig. 7C actually indicates that IKKalpha targets IRF3 on other S/T residues or that it plays downstream of this transcription factor. Thus, the following specific issues must be addressed to substantiate this part of the study: (1) Is IKKalpha required for IRF3 dimerization and coactivator association? (2) Do IKKalpha and IRF3 interact together? (3) The preferred phosphorylation motif of IKKalpha in terms of amino acids adjacent to the actual phosphorylation site is a hydrophobic amino acid (L) in the +1 position (Marinis, MCB 2012) . It is interesting to note that S386, which has been identified as being critical for IRF3 activation (Mori et al., JBC 2004) , also contains a Leu in the +1 position. Thus, mass spectrometry analysis should be performed on IRF3 incubated with recombinant IKKalpha. If IKKalpha preferentially plays a role downstream of IRF3, is this through its ability to phosphorylate and increase the HAT activity of CBP ( This is an very solid study that defines a role for IKK-alpha in DCs, for the ability of DCs to function in the priming of T cell responses in vivo and in the optimal phosphorylation of IRF3 that functions in the activation of cytokine production. I would suggest that the final experiments might be able to be improved to add some specificity to the proposed observation that IKK-alpha CAN phosphorylate the terminus of IRF3 in the region 396-405.
I have essentially no problems with most of the data or interpretations, particularly the in vivo data. The first four figures are a clear analysis of the in vivo analysis of immune responses in IKK-alpha mutant (AA/AA) mice that were described by Karin in 2001 with a mammary gland phenotype. These mice (and other mice with a deletion of IKK-alpha by CD11c-Cre) are examine for T cell priming, memory responses to Listeria infection, maturation of DCs induced by TLR stimulation (Figures 1-3 ). I don't see why the conditional deletion data should be kept out as a supplemental figure. It is important to show that the effect is intrinsic to DCs. I would suggest including some of the supplemental data in main figures. The analysis in Figure 4 shows a requirement for IRF3 in cytokine production by OTII T cells in response to antigen and TLR priming. I am not sure why the authors showed that there was no additional deficiency in the IRF3/7 DKO, without examining the IRF7 KO along side. This lack of a control (the IRF7 single KO) might be one rare gap in the study.
The second part of the study proposes the new finding connecting IKK-alpha to activation of IRF3, initially by showing a similarity in the phenotype of the two knockout mice for cytokine production induced by priming with antigen and TLR stimulation. The cytokines IL-12 and IFN-beta are both shown to be dependent on IRF3. There is a selective loss of IFN-beta-reporter activity in IKK-alpha ko cells, but not in IKK-beta KO cells (Fig. 6 ). Since IKK-alpha KO cells still gave Ser396 phosphorylation (Fig. 6C) , the authors make an inference that the region 396-405 having 5 serine residues, may be the target of IKK-alpha activity. The authors wish to offer Fig 7D as the final evidence for the activity of IKK-alpha in regulating IRF3-dependent activity for transcription of cytokine genes. This experiment is a GST-IRF3-396-405 in vitro kinase assay, show a potential for this being the substrate. I think it might not be considered as strong proof at this point, as this in vitro kinase assay has not been offered with specificity controls, positive or negative. I would worry most about the possibility that the in vitro activity is true, but that this is not really how IKK-alpha is regulating IRF3 activity in vivo.
I could suggest one of two routes for the authors. I would think that everything up to Fig. 7C is publishable as is. The functional link to IRF3 seems solid, and apparently new. But it would be a shame if the authors spoiled this with a weak final claim that turns out to be off target. Perhaps IKKalpha is only required to allow another kinase to be able to phosphorylate this regions, acting as a scaffold. Perhaps IKK-alpha acts on another target site that is unknown at present but required for IRF3 activity. At least the authors might add some controls to the final experiment and to address this issue a little more cautiously, as a hedge. We have used the phospho-IKKα/β antibody to measure TAK1-dependent IKKα/β activation and it's implication in TLR4/3-mediated IFNβ expression in BMDC. Unfortunately, there is no specific antibody for phosphorylated IKKα, the antibody used cross-reacts with both phosphorylated IKKβ and IKKα, and with somewhat higher signal for pIKKβ than pIKKα. However, pIKKα/β can be distinguished by size (85/89 kDa, respectively), in BMDC the antibody also detects a non-specific band that unfortunately often masks the signal of phosphorylated IKKα, the resolution of the pIKKα is therefore quite variable. We have included a blot of pIKKα/β analysis in polyI:C-stimulated BMDC that more clearly illustrates pIKKα with a low cross-reactivity of the non-specific band (Fig.5B ). We have also tested a pTAK1 antibody but unfortunately this antibody does not give a satisfactory signal with BMDC in our hands. TAK1 is well established to regulate both IKK and JNK activation downstream of TLR4. However, a specific JNK inhibitor had only a partial effect on LPS and polyI:C-induced IFNβ expression in BMDC (Fig.S12B) , whereas the TAK1 inhibitor almost completely blocked IFNβ (Fig.5B,C) . These data suggest TAK1-mediated JNK activation only partially contributes to IFNβ expression and TAK1-mediated IKKα/β activation also has a significant role. We have now analysed LPS and polyI:C-induced IFNβ expression in TAK1 (Map3k7) knockout BMDC. IFNβ expression was significantly inhibited in TAK1 deficient BMDC (Fig.5F ). However, while IKKα/β phosphorylation was inhibited by TAK1 deletion, there was little effect on JNK activity (Fig.5E ), suggesting TAK1-mediated IKKα/β activation may have a dominant role over JNK in TLR4/3-induced IFNβ expression. In addition, we found no change in LPS or polyI:C-induced JNK activation in Ikkα AA/AA BMDC (Fig.S12A) , indicating reduced IFNβ expression in Ikkα AA/AA DC is not attributed to effects on JNK activation.
"3) Figure 5 relies on the use of drug inhibitors. Other molecular means such as RNA interference should also be employed to take into consideration the possible "off-target" effects of the pharmacological approach. In addition, the proteasome inhibitor MG132 is not an NF-kappaB inhibitor; it inhibits the degradation of all proteins targeted to the proteasome. Other inhibitors, such as MLN4924, prevent the NEDDylation and hence the activation of SCFβTRCP (and other Cullin-based RING E3 ligases) and block the polyubiquitylation of phosphorylated IkappaBalpha and therefore its degradation."
We have performed experiments with TAK1 knockout BMDC (see response to comment 2) that validate our results with the TAK1 inhibitor (Fig.5E,F) . We have also repeated the experiments with MG132 using MLN4924, as the referee suggested. These results also validate those obtained with MG132, reiterating the NF-κB-independent role for TAK1 in IFNβ expression (Fig.5C,D) .
"4) The proposed TAK1-IKKalpha axis (pages 16 and 17) is rather weak and should be carefully discussed. In the present version of the manuscript, I am not convinced that the use of the TAK1 inhibitor prevented IKKalpha phosphorylation (see comment #1). In addition, a TAK1-JNK cascade (independent of IKKalpha) was previously proposed to be involved in IRF3 function (Zhang et al., Cell Research 2009)."
See above response to comments 2 and 3.
"5) The authors conclude that IKKalpha regulates IRF3-mediated transcription downstream of IKKe/TBK1, possibly through direct phosphorylation of IRF3 (Figure 7). At this stage, the presented data do not support such a conclusion: (1) Is IKKalpha required for IRF3 dimerization and coactivator association?"
We were not able to reliably detect CBP/p300 association with endogenous IRF3 by coimmunoprecipitation (co-IP) in BMDC, however using a transfection approach in HEK293T cells stably expressing TLR3 we can demonstrate that overexpression of IKKα, but not the IKKα AA mutant, promotes the association of IRF3 with CBP ( Fig.7A) , furthermore the enhanced recruitment of CBP is associated with a direct interaction between IKKα and IRF3. The increased recruitment of CBP after over-expression of IKKα is also associated with increased transcription of IFNβ mRNA (Fig.7B) . The inability of IKKα AA to promote CBP recruitment or increased IFNβ transcription illustrates the requirement for IKKα kinase activity.
"(2) Do IKKalpha and IRF3 interact together?"
See response above. (Marinis, MCB 2012) . It is interesting to note that S386, which has been identified as being critical for IRF3 activation (Mori et al., JBC 2004) , also contains a Leu in the +1 position. Thus, mass spectrometry analysis should be performed on IRF3 incubated with recombinant IKKalpha."
"(3) The preferred phosphorylation motif of IKKalpha in terms of amino acids adjacent to the actual phosphorylation site is a hydrophobic amino acid (L) in the +1 position
Unfortunately we do not have the expertise or equipment to perform phosphopeptide mapping by mass spectrometry. However, we have further analysed the specific residues in the C-terminal regulatory domain of IRF3 that are phosphorylated by IKKα using various C-terminal peptides with point mutations in specific serine residues. We have established that the major phosphorylation sites for IKKα are Ser402/Thr404/Ser405 (Fig.7D) . Phosphorylation of the 402/404/405 cluster of residues has previously been shown to contribute to IRF3 activation in response to viral infection (Lin et al, 1998) . There appeared to be no significant IKKα-mediated phosphorylation of IRF3 at Ser396/Ser398 or Ser385/Ser386, thus supporting our conclusion that IKKα-mediated regulation of IRF3 activity is independent of TBK1/IKKε-mediated phosphorylation of Ser396. O'Connell et al., J.Exp. Med. 2004) . If the novel signaling cascade composed of IKKalpha-IRF3 is indeed relevant in response to infection, it could partly explain the early protective profile observed upon infection of IKKalphaAA chimeric mice (Fig. 2) . Is there less splenic apoptosis in IKKalphaAA mice?"
Minor concerns:

"-It has previously been shown that IRF3 activation inhibits the ability of infected mice to control L. monocytogenes growth during the early stages of infection (through IRF3 and IFNAR1-induced massive apoptosis in lymphocyte-rich follicles in the spleens of L. monocytogenes-infected wild-type mice by 2 d after infection;
We have suggested exactly this mechanism in our discussion, since we have previously established that IKKα promotes macrophage apoptosis in the context of infection. However, we have not performed this specific analysis in these experiments.
Referee #2: "1) I don't see why the conditional deletion data should be kept out as a supplemental figure. It is important to show that the effect is intrinsic to DCs. I would suggest including some of the supplemental data in main figures."
We have added this figure to the main manuscript as suggested. Figure 4 shows a requirement for IRF3 in cytokine production by OTII T cells in response to antigen and TLR priming. I am not sure why the authors showed that there was no additional deficiency in the IRF3/7 DKO, without examining the IRF7 KO along side. This lack of a control (the IRF7 single KO) might be one rare gap in the study."
"The analysis in
We included the IRF3/7 DKO cells to control for any potential IRF3-independent role of IRF7 in IFNβ expression, since IRF7 can directly regulate MyD88-mediated IFNα/β expression in pDC. However, since TLR4/3-mediated IFNβ expression in BMDC was completely IRF3-dependent this control turns out to be somewhat redundant. Fig 7D as We have extended the analysis of IKKα-mediated IRF3 phosphorylation and can now describe the specific residues within the C-terminal domain of IRF3 that are phosphorylated by IKKα. Furthermore, we now demonstrate a strong biochemical interaction between IKKα and IRF3 by co-IP, which is associated with enhanced CBP-recruitment (see response to referee #1 comment 5), thus directly linking IKKα to the transcriptional activity of IRF3. Thank you for submitting your revised version to the EMBO Journal. Your study has now been rereviewed by referee #1. As you can see below referee #1 appreciates the added data and supports publication here. There are just a few minor issues to be resolved before acceptance here that shouldn't involve too much additional work.
"The authors wish to offer
Also, we now encourage the publication of source data, particularly for electrophoretic gels and blots, with the aim of making primary data more accessible and transparent to the reader. Would you be willing to provide a PDF file per figure that contains the original, uncropped and unprocessed scans of all or key gels used in the figure? The PDF files should be labeled with the appropriate figure/panel number, and should have molecular weight markers; further annotation could be useful but is not essential. The PDF files will be published online with the article as supplementary "Source Data" files. If you have any questions regarding this just contact me.
Once we receive the revised manuscript we will accept the study for publication here.
Thank you for submitting your interesting study to the EMBO Journal.
REFEREE REPORTS
Referee #1
Whereas most of my criticisms were satisfactorily answered, the presented new sets of data, particularly those presented in the new Fig 7, still raise some questions:
-New Fig. 7A shows that ectopically expressed IKKalpha in 293T-TLR3 cells increases the ability of IRF3 to associate with CBP. It is proposed that the kinase activity of IKKalpha is required in this process. However, ectopic expression of the IKKalphaAA mutant did not prevent p(I:C)-induced IRF3 association with CBP (when compare to cells transfected with the vector alone). The present reviewer is thus questioning the absence of a dominant negative effect of overexpressed IKKalphaAA mutant in this particular assay.
-New Fig. 7C demonstrates that recombinant IKKalpha preferentially target cluster III using in vitro kinase assays. In addition to the use of ectopically expressed IRF3, an IRF3 cluster III mutant (IRF3 402/4/5 alanine) need to be tested in the qRT-PCR assays show in new Fig. 7B . This is required to functionally and molecularly linked IKKalpha to the phosphorylation of cluster III.
-Former Fig. 7C showed that the transcriptional activity of IRF3/5D was further increase by ectopically expressed IKKalpha. If IKKalpha really targets cluster III in vivo, then it should not affect the transcriptional activity of the non-phosphorylable IRF3/5D mutant. Although this data is no longer part of this version, the present reviewer whould like the authors to comment such observations. 
